Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
1r67f9yf5tT1fdSq
Listen
